We demonstrated that Flk-1(+) cells derived from mouse embryonic stem (ES) cells can differentiate into both endothelial cells (ECs) and mural cells (MCs) to suffice as vascular progenitor cells (VPCs). In the present study, we investigated the importance of the stage of ES cell differentiation on effective participation in adult neovascularization. We obtained Flk-1(+) LacZ-expressing undifferentiated VPCs. Additional culture of these VPCs with vascular endothelial growth factor (VEGF) resulted in a mixture of ECs and MCs (differentiated VPCs). We injected VPCs subcutaneously into tumor-bearing mice. Five days after the injection, whereas undifferentiated VPCs were often detected as nonvascular cells, differentiated VPCs were more specifically incorporated into developing vasculature mainly as ECs. VPC-derived MCs were also detected in vascular walls. Furthermore, transplantation of differentiated VPCs augmented tumor blood flow in nude mice. These results indicate that a specific vascular contribution in adult neovascularization can be achieved by selective transplantation of ES cell-derived VPCs in appropriate differentiation stages, which should be the basis for vascular regeneration schemes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1182/blood-2002-06-1877 | DOI Listing |
Asian Pac J Cancer Prev
December 2024
Department of Hematology, Theodor Bilharz Research Institute (TBRI), Giza, Egypt.
Background: The Tie2/Ang pathway was found to be involved in forming tumor blood vessels in various tumors. The goal of this study was to evaluate the value of Tie2/Ang pathway as a novel biomarkers for the early detection of chronic hepatitis C virus (CHC)-related hepatocellular carcinoma (HCC). And the possibility of their future application in HCC treatment.
View Article and Find Full Text PDFThe introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.
View Article and Find Full Text PDFPurpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Vestn Oftalmol
December 2024
Novosibirsk State Regional Hospital, Novosibirsk, Russia.
Purpose: This study evaluated the impact of phacoemulsification cataract surgery (PE) on anatomical and functional parameters, as well as the regimen and frequency of anti-VEGF injections in patients with neovascular age-related macular degeneration (nAMD) over a long-term period (up to 3 years).
Material And Methods: The study included 117 patients (117 eyes) diagnosed with nAMD and cataract, graded by LOCS: LOCS I (=56; 47.9%), LOCS II (=57; 48.
Indian J Ophthalmol
January 2025
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon.
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Methods: Retrospective chart review of patients with nAMD previously treated with aflibercept for at least 12 months and subsequently transitioned to ziv-aflibercept between January 1, 2019, and December 31, 2022, for a period of at least 12 months. Participants were identified, and their clinical and imaging information was extracted from our electronic health records system.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!